- Home
- CGEM
as 07-26-2024 4:00pm EST
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.1B | IPO Year: | 2021 |
| Target Price: | $32.00 | AVG Volume (30 days): | 850.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.64 - $30.19 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Cullinan Oncology Inc. (CGEM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Michaelson Jennifer | CGEM | Chief Scientific Officer | May 6 '24 | Sell | $27.82 | 37,723 | $1,049,453.86 | 149,859 | SEC Form 4 |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | May 6 '24 | Sell | $28.54 | 20,277 | $578,705.58 | 129,582 | SEC Form 4 |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | May 6 '24 | Sell | $30.06 | 5,606 | $168,516.36 | 129,582 | SEC Form 4 |
| Savill Corrine | CGEM | Chief Business Officer | Feb 1 '24 | Sell | $16.18 | 40,000 | $647,200.00 | 165,990 | SEC Form 4 |
| Savill Corrine | CGEM | Chief Business Officer | Jan 29 '24 | Sell | $14.09 | 40,000 | $563,600.00 | 165,990 | SEC Form 4 |
| Savill Corrine | CGEM | Chief Business Officer | Jan 22 '24 | Sell | $12.18 | 14,559 | $177,328.62 | 170,115 | SEC Form 4 |
| Savill Corrine | CGEM | Chief Business Officer | Jan 22 '24 | Sell | $12.02 | 4,125 | $49,582.50 | 165,990 | SEC Form 4 |
| Savill Corrine | CGEM | Chief Business Officer | Jan 22 '24 | Sell | $12.46 | 21,316 | $265,597.36 | 165,990 | SEC Form 4 |
| AHMED NADIM | CGEM | President and CEO | Dec 26 '23 | Sell | $9.24 | 4,272 | $39,473.28 | 111,550 | SEC Form 4 |
| Trigilio Jeffrey | CGEM | Chief Financial Officer | Dec 21 '23 | Sell | $8.50 | 1,920 | $16,320.00 | 83,919 | SEC Form 4 |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 21 '23 | Sell | $8.50 | 1,145 | $9,732.50 | 87,582 | SEC Form 4 |
| Trigilio Jeffrey | CGEM | Chief Financial Officer | Dec 18 '23 | Sell | $8.22 | 398 | $3,271.56 | 85,839 | SEC Form 4 |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 18 '23 | Sell | $8.22 | 238 | $1,956.36 | 88,727 | SEC Form 4 |
| Jones Jeffrey Alan | CGEM | Chief Medical Officer | Dec 18 '23 | Sell | $8.22 | 386 | $3,172.92 | 58,051 | SEC Form 4 |
| SUMER JACQUELYN L | CGEM | Chief Legal Officer | Dec 18 '23 | Sell | $8.22 | 290 | $2,383.80 | 45,533 | SEC Form 4 |
| Trigilio Jeffrey | CGEM | Chief Financial Officer | Dec 12 '23 | Sell | $7.81 | 1,926 | $15,042.06 | 86,237 | SEC Form 4 |
| Michaelson Jennifer | CGEM | Chief Scientific Officer | Dec 12 '23 | Sell | $7.81 | 1,068 | $8,341.08 | 88,965 | SEC Form 4 |
Latest Cullinan Oncology Inc. News
CGEM Breaking Stock News: Dive into CGEM Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 months ago
Institutional owners may ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) recent US$92m market cap decline as longer-term profits stay in the green
Clinical Trials Arena
2 months ago
Cullinan Therapeutics announces success for zipalertinib as combo therapy
GlobeNewswire
2 months ago
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
GlobeNewswire
2 months ago
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
GlobeNewswire
2 months ago
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
MT Newswires
2 months ago
HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating
GlobeNewswire
2 months ago
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
GuruFocus.com
3 months ago
Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...
Compare CGEM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CGEM Cullinan Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.